Optimal biological dose: a systematic review in cancer phase I clinical trials

BACKGROUND: Classical phase 1 dose-finding designs based on a single toxicity endpoint to assess the maximum tolerated dose were initially developed in the context of cytotoxic drugs. With the emergence of molecular targeted agents and immunotherapies, the concept of optimal biological dose (OBD) wa...

Descripción completa

Detalles Bibliográficos
Autores principales: Fraisse, J., Dinart, D., Tosi, D., Bellera, C., Mollevi, C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7805102/
https://www.ncbi.nlm.nih.gov/pubmed/33441097
http://dx.doi.org/10.1186/s12885-021-07782-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7805102/
https://www.ncbi.nlm.nih.gov/pubmed/33441097
http://dx.doi.org/10.1186/s12885-021-07782-z

Ejemplares similares